Lam Research Corporation $LRCX Stake Cut by Retirement Systems of Alabama

Retirement Systems of Alabama cut its holdings in shares of Lam Research Corporation (NASDAQ:LRCX) by 0.5% in the second quarter, HoldingsChannel reports. The fund owned 274,474 shares of the semiconductor company’s stock after selling 1,372 shares during the quarter. Retirement Systems of Alabama’s holdings in Lam Research were worth $26,717,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. BankPlus Wealth Management LLC boosted its holdings in shares of Lam Research by 2.0% during the second quarter. BankPlus Wealth Management LLC now owns 5,248 shares of the semiconductor company’s stock worth $511,000 after purchasing an additional 105 shares during the period. ORG Partners LLC increased its stake in Lam Research by 7.3% in the 2nd quarter. ORG Partners LLC now owns 1,676 shares of the semiconductor company’s stock valued at $162,000 after buying an additional 114 shares during the period. Quotient Wealth Partners LLC lifted its position in Lam Research by 2.1% in the 2nd quarter. Quotient Wealth Partners LLC now owns 5,437 shares of the semiconductor company’s stock worth $529,000 after buying an additional 114 shares in the last quarter. Fairvoy Private Wealth LLC boosted its stake in shares of Lam Research by 3.0% during the 2nd quarter. Fairvoy Private Wealth LLC now owns 4,185 shares of the semiconductor company’s stock valued at $407,000 after buying an additional 120 shares during the period. Finally, Rosenberg Matthew Hamilton grew its holdings in shares of Lam Research by 16.0% during the 2nd quarter. Rosenberg Matthew Hamilton now owns 869 shares of the semiconductor company’s stock valued at $85,000 after acquiring an additional 120 shares in the last quarter. Institutional investors and hedge funds own 84.61% of the company’s stock.

Wall Street Analysts Forecast Growth

LRCX has been the subject of several recent research reports. Citigroup increased their price objective on Lam Research from $120.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Summit Insights lowered Lam Research from a “buy” rating to a “hold” rating in a research report on Thursday, July 31st. Dbs Bank raised their price target on Lam Research from $119.40 to $184.20 in a research note on Monday. Erste Group Bank initiated coverage on Lam Research in a research note on Thursday, August 14th. They issued a “buy” rating for the company. Finally, Cowen restated a “buy” rating on shares of Lam Research in a report on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-six have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $148.54.

Insider Activity

In related news, SVP Vahid Vahedi sold 52,190 shares of the stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $138.90, for a total transaction of $7,249,191.00. Following the completion of the sale, the senior vice president owned 251,047 shares in the company, valued at $34,870,428.30. This represents a 17.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ava Harter sold 9,010 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $157.47, for a total value of $1,418,804.70. Following the completion of the sale, the insider directly owned 56,786 shares in the company, valued at $8,942,091.42. This trade represents a 13.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.31% of the stock is currently owned by insiders.

Lam Research Trading Up 0.2%

NASDAQ:LRCX opened at $161.01 on Friday. The company’s 50 day moving average is $127.98 and its 200-day moving average is $102.36. The company has a quick ratio of 1.60, a current ratio of 2.21 and a debt-to-equity ratio of 0.37. Lam Research Corporation has a 12 month low of $56.32 and a 12 month high of $165.22. The firm has a market cap of $202.23 billion, a price-to-earnings ratio of 35.46, a P/E/G ratio of 1.68 and a beta of 1.84.

Lam Research (NASDAQ:LRCX) last posted its earnings results on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.04. The business had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.23 billion. Lam Research had a net margin of 29.66% and a return on equity of 60.60%. Lam Research’s revenue was up 27.7% compared to the same quarter last year. During the same period last year, the business posted $0.86 EPS. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. Equities analysts anticipate that Lam Research Corporation will post 3.71 EPS for the current year.

Lam Research Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 15th. Stockholders of record on Wednesday, September 24th were paid a $0.26 dividend. The ex-dividend date was Wednesday, September 24th. This is a boost from Lam Research’s previous quarterly dividend of $0.23. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.6%. Lam Research’s dividend payout ratio is presently 22.91%.

Lam Research Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.